watching it as well - summary of session 3 (MSCs for patients with COVID-19)
Josh Hare - MSCs for COVID under EAP
14 patients (9 on ECMO) - 78% survival vs 55% in control group), suggested function of MSCs for COVID beyond just the lungs (heart mentioned)
Joan Kurtzberg
Looking at MIS-C using MSCs (not Mesoblast cells) - no data as yet but linked the mesoblast data demonstrating reduction of inflammation, safety over 10 yrs across 4000 doses delivered to kids (infants to 10) as a contributing factor as to why she thinks it will work. Phase 1 will be 4 doses @ 2millions cells/kg
Wenchun Qu - meta analysis - 5 comparative studies with control/treatment groups (179 patients total). 4 studies showed decreased mortality, 1 increased. Overall mortality was 25% for treated cf 43% controls ie 75% survival vs 57% survival)
From the data - Hare, Qu and MSB survivals are comparable (78%, 75% and 83% respectively) - 'control' survivals were similar (55%, 57% and IIRC, we are expecting around 50% survival for the current MSB phase 3?)
- Forums
- ASX - By Stock
- MSB
- MESO action tonight
MESO action tonight, page-2499
-
-
- There are more pages in this discussion • 661 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.5¢ |
Change
-0.070(6.57%) |
Mkt cap ! $1.136B |
Open | High | Low | Value | Volume |
$1.04 | $1.04 | 99.5¢ | $3.980M | 3.944M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 56239 | 99.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 103125 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 56239 | 0.995 |
11 | 88118 | 0.990 |
3 | 28311 | 0.985 |
9 | 97667 | 0.980 |
4 | 43265 | 0.975 |
Price($) | Vol. | No. |
---|---|---|
1.000 | 103125 | 2 |
1.005 | 30000 | 1 |
1.010 | 93156 | 7 |
1.015 | 38710 | 2 |
1.020 | 107691 | 4 |
Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |